Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 1, 2016, Pages 156-165

  Mendivil, Carlos O ^a,b,c   Furtado, Jeremy ^c   Morton, Allyson M ^c   Wang, Liyun ^c   Sacks, Frank M ^c,d  

^a UNIVERSIDAD DE LOS ANDES   (Colombia)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

apolipoprotein; cholesterol; high density lipoprotein; liver; metabolism

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; APOA1 PROTEIN, HUMAN; BIOLOGICAL MARKER; PRE BETA HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; FEMALE; HUMAN; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; MALE; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; BIOLOGICAL MODEL; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; KINETICS; LIVER; METABOLISM; PARTICLE SIZE;

ADULT; APOLIPOPROTEIN A-I; BIOMARKERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; FEMALE; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; KINETICS; LIPOPROTEINS, HDL; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OVERWEIGHT; PARTICLE SIZE;

EID: 84952639394     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306138     Document Type: Article

References (52)

1. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J, Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 302 1993 2000. doi: 10.1001/jama.2009.1619
2. Thompson A, Danesh J, Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006 259 481 492. doi: 10.1111/j.1365-2796.2006.01644.x
3. Voight BF, Peloso GM, Orho-Melander M, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012 380 572 580. doi: 10.1016/S0140-6736(12)60312-2
4. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011 365 2255 2267. doi: 10.1056/NEJMoa1107579
5. Barter PJ, Caulfield M, Eriksson M, ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 2109 2122. doi: 10.1056/NEJMoa0706628
6. Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797
7. Shah AS, Tan L, Long JL, Davidson WS, Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 2013 54 2575 2585. doi: 10.1194/jlr.R035725
8. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD, High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012 32 2813 2820. doi: 10.1161/ATVBAHA.112.300133
9. Heinecke J, HDL and cardiovascular-disease risk-time for a new approach? N Engl J Med 2011 364 170 171. doi: 10.1056/NEJMe1012520
10. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L, Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012 125 1905 1919. doi: 10.1161/CIRCULATIONAHA.111.066589
11. Rader DJ, Hovingh GK, HDL and cardiovascular disease. Lancet 2014 384 618 625. doi: 10.1016/S0140-6736(14)61217-4
12. Rye KA, Barter PJ, Cardioprotective functions of HDLs. J Lipid Res 2014 55 168 179. doi: 10.1194/jlr.R039297
13. Rye KA, Barter PJ, Regulation of high-density lipoprotein metabolism. Circ Res 2014 114 143 156. doi: 10.1161/CIRCRESAHA.114.300632
14. Westerterp M, Bochem AE, Yvan-Charvet L, Murphy AJ, Wang N, Tall AR, ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ Res 2014 114 157 170. doi: 10.1161/CIRCRESAHA.114.300738
15. Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, Hoekstra M, Sierts JA, Dallinga-Thie GM, Motazacker MM, Holleboom AG, Van Berkel TJ, Kastelein JJ, Van Eck M, Kuivenhoven JA, Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011 364 136 145. doi: 10.1056/NEJMoa0907687
16. Colvin PL, Moriguchi E, Barrett PH, Parks JS, Rudel LL, Small HDL particles containing two apoA-I molecules are precursors in vivo to medium and large HDL particles containing three and four apoA-I molecules in nonhuman primates. J Lipid Res 1999 40 1782 1792
17. Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, Baki T, Rothblat G, de la Llera-Moya M, Asztalos B, Perlman T, Zheng C, Alaupovic P, Maltais JA, Brewer HB, Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 2009 50 894 907. doi: 10.1194/jlr.M800622-JLR200
18. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T, Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 2004 45 174 185. doi: 10.1194/jlr.M300309-JLR200
19. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG, Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003 52 803 811
20. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Nyaku M, Horvath KV, Asztalos BF, Otokozawa S, Ai M, Matthan NR, Lichtenstein AH, Dolnikowski GG, Schaefer EJ, Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008 28 1672 1678. doi: 10.1161/ATVBAHA.108.164541
21. Walsh BW, Li H, Sacks FM, Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 1994 35 2083 2093
22. Brinton EA, Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol 1996 16 431 440
23. Li X, Stolinski M, Umpleby AM, Development of a method to measure preβHDL and αHDL apoA-I enrichment for stable isotopic studies of HDL kinetics. Lipids 2012 47 1011 1018. doi: 10.1007/s11745-012-3703-0
24. Zheng C, Khoo C, Furtado J, Sacks FM, Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010 121 1722 1734. doi: 10.1161/CIRCULATIONAHA.109.875807
25. Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G, Bedynek A, Shepherd J, Seidel D, Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 2000 41 305 318
26. Grundy SM, Vega GL, Kesäniemi YA, Abnormalities in metabolism of low density lipoproteins associated with coronary heart disease. Acta Med Scand Suppl 1985 701 23 37
27. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN, Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993 91 1743 1752. doi: 10.1172/JCI116384
28. Gylling H, Vega GL, Grundy SM, Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. J Lipid Res 1992 33 1527 1539
29. Brinton EA, Eisenberg S, Breslow JL, Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994 14 707 720
30. Ooi EM, Watts GF, Farvid MS, Chan DC, Allen MC, Zilko SR, Barrett PH, High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res 2005 13 1008 1016. doi: 10.1038/oby.2005.118
31. Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ, Marsh JB, Effect of body mass index on apolipoprotein A-I kinetics in middle-aged men and postmenopausal women. Metabolism 2007 56 910 914. doi: 10.1016/j.metabol.2007.01.022
32. Brewer HB Jr, Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 2011 96 1246 1257. doi: 10.1210/jc.2010-0163
33. Lund-Katz S, Lyssenko NN, Nickel M, Nguyen D, Chetty PS, Weibel G, Phillips MC, Mechanisms responsible for the compositional heterogeneity of nascent high density lipoprotein. J Biol Chem 2013 288 23150 23160. doi: 10.1074/jbc.M113.495523
34. Ji A, Wroblewski JM, Cai L, de Beer MC, Webb NR, van der Westhuyzen DR, Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. J Lipid Res 2012 53 446 455. doi: 10.1194/jlr.M017079
35. Chisholm JW, Burleson ER, Shelness GS, Parks JS, ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J Lipid Res 2002 43 36 44
36. Zheng H, Kiss RS, Franklin V, Wang MD, Haidar B, Marcel YL, ApoA-I lipidation in primary mouse hepatocytes. Separate controls for phospholipid and cholesterol transfers. J Biol Chem 2005 280 21612 21621. doi: 10.1074/jbc.M502200200
37. Kiss RS, McManus DC, Franklin V, Tan WL, McKenzie A, Chimini G, Marcel YL, The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and-independent pathways. J Biol Chem 2003 278 10119 10127. doi: 10.1074/jbc.M300137200
38. Sorci-Thomas MG, Owen JS, Fulp B, Bhat S, Zhu X, Parks JS, Shah D, Jerome WG, Gerelus M, Zabalawi M, Thomas MJ, Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J Lipid Res 2012 53 1890 1909. doi: 10.1194/jlr.M026674
39. Mulya A, Lee JY, Gebre AK, Thomas MJ, Colvin PL, Parks JS, Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol 2007 27 1828 1836. doi: 10.1161/ATVBAHA.107.142455
40. Liu L, Bortnick AE, Nickel M, Dhanasekaran P, Subbaiah PV, Lund-Katz S, Rothblat GH, Phillips MC, Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles. J Biol Chem 2003 278 42976 42984. doi: 10.1074/jbc.M308420200
41. Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J Jr, Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem 2004 279 7384 7394. doi: 10.1074/jbc.M306963200
42. Glomset JA, The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase. Biochim Biophys Acta 1962 65 128 135
43. Forte T, Norum KR, Glomset JA, Nichols AV, Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: structure of low and high density lipoproteins as revealed by elctron microscopy. J Clin Invest 1971 50 1141 1148. doi: 10.1172/JCI106586
44. Furbee JW Jr, Francone O, Parks JS, Alteration of plasma HDL cholesteryl ester composition with transgenic expression of a point mutation (E149A) of human LCAT. J Lipid Res 2001 42 1626 1635
45. Colvin P, Moriguchi E, Barrett H, Parks J, Rudel L, Production rate determines plasma concentration of large high density lipoprotein in non-human primates. J Lipid Res 1998 39 2076 2085
46. Randolph GJ, Miller NE, Lymphatic transport of high-density lipoproteins and chylomicrons. J Clin Invest 2014 124 929 935. doi: 10.1172/JCI71610
47. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE, Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001 42 1586 1593
48. Huang R, Silva RA, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, Hodges TJ, Davidson WS, Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011 18 416 422. doi: 10.1038/nsmb.2028
49. Korhonen A, Jauhiainen M, Ehnholm C, Kovanen PT, Ala-Korpela M, Remodeling of HDL by phospholipid transfer protein: demonstration of particle fusion by 1H NMR spectroscopy. Biochem Biophys Res Commun 1998 249 910 916. doi: 10.1006/bbrc.1998.9162
50. Rye KA, Hime NJ, Barter PJ, Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J Biol Chem 1997 272 3953 3960
51. Clay MA, Newnham HH, Forte TM, Barter PI, Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim Biophys Acta 1992 1124 52 58
52. Nguyen D, Nickel M, Mizuguchi C, Saito H, Lund-Katz S, Phillips MC, Interactions of apolipoprotein A-I with high-density lipoprotein particles. Biochemistry 2013 52 1963 1972. doi: 10.1021/bi400032y